Slotta Jan Erik, Kollmar Otto, Ellenrieder Volker, Ghadimi B Michael, Homayounfar Kia
Jan Erik Slotta, Otto Kollmar, B Michael Ghadimi, Kia Homayounfar, Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, D-37075 Goettingen, Germany.
World J Hepatol. 2015 May 28;7(9):1168-83. doi: 10.4254/wjh.v7.i9.1168.
Hepatocellular carcinoma (HCC) is the most common liver-derived malignancy with a high fatality rate. Risk factors for the development of HCC have been identified and are clearly described. However, due to the lack of tumor-specific symptoms, HCC are diagnosed at progressed tumor stages in most patients, and thus curative therapeutic options are limited. The focus of this review is on surgical therapeutic options which can be offered to patients with HCC with special regard to recent findings, not exclusively focused on surgical therapy, but also to other treatment modalities. Further, potential promising future perspectives for the treatment of HCC are discussed.
肝细胞癌(HCC)是最常见的源自肝脏的恶性肿瘤,死亡率很高。HCC发生的风险因素已被确定并得到清晰描述。然而,由于缺乏肿瘤特异性症状,大多数患者在肿瘤进展阶段才被诊断出HCC,因此根治性治疗选择有限。本综述的重点是可提供给HCC患者的手术治疗选择,特别关注近期的研究结果,不仅专门聚焦于手术治疗,还涉及其他治疗方式。此外,还讨论了HCC治疗未来潜在的有前景的观点。